Q
QuantAbundance

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

30,897 signal articles · 27 in last 24h · 157,635 total before filter · latest 17h ago
27last 24h
753last 7d
119● bullish (7d)
73● bearish (7d)
214publishers
AllMacro179Earnings128M&A82Regulatory15Product14Analyst19
✕ clear all filterssentiment: bearishSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Bloomberg68d agobearish
Uber Cuts 10% of Customer Service Jobs, Citing ‘Embrace’ of AI

(Bloomberg) -- Uber Technologies Inc. said it has cut 10% of jobs within its customer service operations as part of a broader effort to simplify its ranks and “embrace artificial intelligence.” Most Read from BloombergTrump’s 100% Generic Drug Duty Threatens US Low-Cost SupplyApple Plans Overhaul of MacBooks, iMac in Push to Meet AI DemandHegseth Turns to UNC, Virginia Tech After Dropping Ivy LeagueApple to Launch ‘Upgrade’ Device Leasing Program With Klarna to Spur SalesTrump Extends Pardons to

IBM (NYSE:IBM) Misses Q2 CY2026 Sales Expectations
StockStory68d agobearish
IBM (NYSE:IBM) Misses Q2 CY2026 Sales Expectations

Technology and consulting giant IBM (NYSE:IBM) fell short of the market’s revenue expectations in Q2 CY2026 as sales only rose 1.1% year on year to $17.16 billion. Its non-GAAP profit of $2.93 per share was in line with analysts’ consensus estimates.

Tesla (TSLA) Misses Q2 Earnings Estimates
Zacks69d agobearish
Tesla (TSLA) Misses Q2 Earnings Estimates

Tesla (TSLA) delivered earnings and revenue surprises of -34.00% and +9.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Pfizer (PFE) Faces Expanded Vaccine Lawsuits On A Fair Value Narrative That Still Sees Upside
Simply Wall St.69d agobearish
Pfizer (PFE) Faces Expanded Vaccine Lawsuits On A Fair Value Narrative That Still Sees Upside

Pfizer (PFE) is back in focus after Arbutus Biopharma and Genevant Sciences expanded their patent litigation over mRNA lipid nanoparticle technology, adding new international cases that raise legal and operational questions for the company’s COVID-19 vaccine business. See our latest analysis for Pfizer. The legal headlines around Pfizer’s mRNA vaccine coincide with a mixed price pattern, with the stock showing a 1-day share price return of 0.77% and a 7-day share price return of 2.85%, but a...

Tesla shares dip after profit misses expectations
AFP69d agobearish
Tesla shares dip after profit misses expectations

Tesla reported weaker-than-expected quarterly profits on Wednesday, citing a hit from lower vehicle prices despite increased auto sales. But the company's earnings press release said profitability was dented by lower vehicle sales prices, lower revenue from regulatory credits and an unspecified "vendor cell issue" that led to an increase in "energy warranty-related charges."